Skip to main content
Robert Popovian on Muck Rack

Robert Popovian

As seen in: Global Healthy Living Foundation, The Hill, Boston Business Journal, Baltimore Sun, National Review, Detroit News, Washington Examiner, STAT, Arizona Daily Star, Morning Consult, The Daily Signal and
Covers:  Drug Pricing, Spending, Affordability and Access
Pharmacist | Economist | Advocate for Patients, Healthcare Professionals and Employers | Truth Teller! Apple/Spotify Podcast: Healthcare Matters

Get in touch with Robert

Contact Robert, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Robert Popovian’s Biography

Read Full Bio →

Robert Popovian is currently Vice President, US Government Relations at Pfizer Inc. where he leads the advocacy function in the U.S. Robert brings over two decades of experience in numerous facets of biopharmaceutical and health care industry with a strong track record of expertise in Health Care Policy and Economics, Government Relations, Medical Affairs, and Strategic Planning.

Robert has published and presented extensively on the impact of biopharmaceuticals and health policies on health ca…

Articles

The American Misdiagnosis — and Mistreatment — of Patient Costs – DC Journal - InsideSources

|
By William Smith, Robert Popovian, Jon DiPietro
| DC Journal
When the federal government decided to enact sweeping price controls on Medicare drugs, pundits and members of Congress crowed that the pharmaceutical industry was finally getting its comeuppance. They claimed that the new law, the Inflation Reduction Act, would make Medicare drugs more affordable and therefore more accessible to U.S. seniors. The only resulting harm would be lower profits for pharmaceutical companies.
Open in Who Shared Issue with article?

Commentary: For the Trump drug plan to succeed, he'll have to get rid of rebates - Providence Business First

|
By William Smith, Robert Popovian
| Boston Business Journal Verified
The Trump administration's “Most Favored Nation” drug pricing hopes to secure prices even lower than Biden's IRA price-control program. The reality of pharmacy benefit managers means that out-of-pocket costs for seniors could go up, not down.
Open in Who Shared Issue with article?

Could the Inflation Reduction Act Maximum Fair Price Hurt Patients?

|
By Anne Sydor, Esteban Rivera, Robert Popovian
| jheor.org
INTRODUCTION As with any complex U.S. federal legislation, the Inflation Reduction Act (IRA), signed into law on August 16, 2022, includes provisions with positive and negative consequences for diverse stakeholders.1 Specific clauses affect health insurance premiums, patients’ out-of-pocket costs, and wholesale medication prices that will impact patients, biopharmaceutical companies, the insurance industry, and policymakers differently, depending on their perspectives and roles within the...
Open in Who Shared Issue with article?
See all 98 licensed articles (103 Total)